Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention

Cardiovascular Research

Volumn 60, Issue 1, 2003, Pages 136-140

  Rahel, Braim M ^a   Visseren, Frank L J ^b   Suttorp, Maarten Jan ^a   Plokker, Thijs H W ^a   Kelder, Johannes C ^a   De Jongh, Bartelt M ^a   Bouter, K Paul ^c   Diepersloot, Rob J A ^d  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Angioplasty; Coronary disease; Endothelial function; Infection inflammation; Restenosis

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; LIPOPROTEIN A; BIOLOGICAL MARKER;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DEATH; DOCUMENTATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INFLAMMATION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RESTENOSIS; TREATMENT OUTCOME; BLOOD; CORONARY ARTERY DISEASE; MIDDLE AGED; MORTALITY; STENT; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE-PHASE PROTEINS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; STENTS; SURVIVAL RATE;

EID: 0642373572     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00355-9     Document Type: Article

References (28)

1. Kuller L., Tracy R., Shaten J., Meilahn E. Relation of C-reactive protein and coronary heart disease in MRFIT nested case-control study, Multiple Risk Factor Intervention Trial. Am J Epidemiol. 144:1996;537-547.
2. Ridker P., Cushman M., Stampfer M., Tracy R., Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
3. Haverkate F., Thompson S., Pyke S., Gallimore J., Pepys M. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
4. Ridker P., Rifai N., Pfeffer M., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
5. Zebrack J., Muhlestein J., Horne B., Anderson J. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 39:2002;632-637.
6. Liuzzo G., Buffon A., Biasucci L., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 98:1998;2370-2376.
7. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol. 82:1998;515-518.
8. Buffon A., Liuzzo G., Biasucci L., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 34:1999;1512-1521.
9. Walter D., Fichtlscherer S., Sellwig M., et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 37:2001;839-846.
10. Hojo Y., Ikeda U., Katsuki T., et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart. 84:2000;83-87.
11. Cooke T., Sheahan R., Foley D., et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation. 89:1994;1593-1598.
12. Montalescot G., Ankri A., Vicaut E., Drobinski G., Grosgogeat Y., Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 92:1995;31-38.
13. Zhou Y., Csako G., Grayston J., et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 84:1999;595-598.
14. Chew D., Bhatt D., Robbins M., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 104:2001;992-997.
15. de Winter R., Heyde G., Koch K., et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J. 23:2002;960-966.
16. Serrano C., Ramires J., Venturinelli M., et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 29:1997;1276-1283.
17. Biasucci L., Liuzzo G., Buffon A., Maseri A. The variable role of inflammation in acute coronary syndromes and in restenosis. Semin Interv Cardiol. 4:1999;105-110.
18. Yeh E., Anderson H., Pasceri V., Willerson J. C-reactive protein. Linking inflammation to cardiovascular complications. Circulation. 104:2001;974-975.
19. Du Clos T. Function of C-reactive protein. Ann Med. 32:2000;274-278.
20. Nakagomi A., Freedman S., Geczy C. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation. 101:2000;1785-1791.
21. Suzuki T., Ishiwata S., Hasegawa K., Yamamoto K., Yamazaki T. Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis. Heart. 83:2000;578.
22. Lloyd G., Jackson G., Foley D., Boersma E., Shepherd J., Serruys P. The influence of plasma lipoprotein(a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis. 158:2001;445-454.
23. Chiarugi L., Prisco D., Antonucci E., et al. Lipoprotein(a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis. 154:2001;129-135.
24. Sirikci O., Aytekin V., Demiroglu I., Demiroglu C., Marcovina S. Association of lipoprotein(a) concentration and apo(a) isoform size with restenosis after percutaneous transluminal coronary angioplasty. Int J Clin Lab Res. 30:2000;93-99.
25. Montalescot G., Ankri A., Vicaut E., Drobinski G., Grosgogeat Y., Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 92:1995;31-38.
26. Naito M., Stirk C., Smith E., Thompson W. Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin E in restenosis and atherogenesis. Thromb Res. 98:2000;165-174.
27. ten Berg J., Hutten B., Kelder J., Verheugt F., Plokker H. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation. 103:2001;2042-2047.
28. Schumacher M., Eber B., Tiran A., et al. Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angioplasty. Cardiology. 80:1992;345-348.